Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125521991 | 12552199 | 1 | I | 20160628 | 20160713 | 20160713 | EXP | NL-CIPLA LTD.-2016NL09433 | CIPLA | 0.00 | Y | 0.00000 | 20160713 | OT | ES | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125521991 | 12552199 | 1 | PS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | UNK, PRIOR THERAPY | U | U | 78759 | ||||||||
| 125521991 | 12552199 | 2 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 1000 MG/M2, EVERY 3 WEEKS | U | U | 78759 | 1000 | MG/M**2 | ||||||
| 125521991 | 12552199 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | UNK, PRIOR THERAPY | U | U | 0 | ||||||||
| 125521991 | 12552199 | 4 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | AUC=6, EVERY 3 WEEKS | U | U | 0 | ||||||||
| 125521991 | 12552199 | 5 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | UNK, PRIOR THERAPY | U | U | 0 | ||||||||
| 125521991 | 12552199 | 6 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | 75 MG/M2, EVERY 3 WEEKS | U | U | 0 | 75 | MG/M**2 | ||||||
| 125521991 | 12552199 | 7 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | UNK, PRIOR THERAPY | U | U | 0 | ||||||||
| 125521991 | 12552199 | 8 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | 175 MG/M2, EVERY 3 WEEKS | U | U | 0 | 175 | MG/M**2 | ||||||
| 125521991 | 12552199 | 9 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | 50 MG/M2, EVERY 4 WEEKS | U | U | 0 | 50 | MG/M**2 | ||||||
| 125521991 | 12552199 | 10 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | UNK, PRIOR THERAPY | U | U | 0 | ||||||||
| 125521991 | 12552199 | 11 | SS | CARLUMAB | CARLUMAB | 1 | Intravenous (not otherwise specified) | 15 MG/KG, EVERY 3 WEEKS | U | U | 0 | 15 | MG/KG | ||||||
| 125521991 | 12552199 | 12 | SS | CARLUMAB | CARLUMAB | 1 | Unknown | 10 MG/KG, EVERY 2 WEEKS | U | U | 0 | 10 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125521991 | 12552199 | 1 | Neoplasm |
| 125521991 | 12552199 | 3 | Neoplasm |
| 125521991 | 12552199 | 5 | Neoplasm |
| 125521991 | 12552199 | 7 | Neoplasm |
| 125521991 | 12552199 | 9 | Neoplasm |
| 125521991 | 12552199 | 11 | Neoplasm |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125521991 | 12552199 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125521991 | 12552199 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |